Literature DB >> 2337903

Fate of intravenously administered rat lymphokine-activated killer cells labeled with different markers.

A A Maghazachi1, L Fitzgibbon.   

Abstract

Rat lymphokine-activated killer (LAK) cells, generated by adhering rat splenocytes isolated from the 52% Percoll density fraction to plastic flasks, demonstrate restricted in vivo tissue distribution, localizing in the lungs and liver after 2 h, but redistributing into the liver and spleen 24 h after i.v. administration. However, a different pattern of distribution was observed when this population of LAK cells was labeled with one of four commonly used radioisotopes. For example, LAK cells showed a high distribution into the lungs 30 min after administration when labeled with 51Cr, 125I-dUrd or 111In-oxine, whereas 111InCl-labeled LAK cells showed an equal distribution into the blood, lungs and liver at this time. Two hours after administration, cells labeled with 111In-oxine showed an equivalent distribution into the lungs and liver, those labeled with 125I-dUrd or 51Cr showed a high accumulation in the lungs, whereas those labeled with 111In-Cl entered more into the liver and blood. The pattern of distribution of 111In-Cl- or 111In-oxine-labeled cells was confirmed using gamma camera imaging analysis. By 24 h, LAK cells labeled with 111InCl, 111In-oxine or 51Cr distributed in the liver and spleen in variable concentrations. In contrast, cells labeled with 125I-dUrd were not detected in any organ tested. This study was paralleled by monitoring the distribution of LAK cells labeled with Hoechst 33342 (H33342) and analyzed for the presence of fluoresceinated cells in different organs either by flow cytometry analysis, or in frozen section. The data indicate that the distribution pattern of LAK cells labeled with 111In-oxine is the closest to the distribution of H33342-labeled cells. Of all the radioisotopes used, 125I-dUrd has the most disadvantages and is not recommended for monitoring the in vivo distribution of leukocytes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2337903     DOI: 10.1007/bf01744727

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  22 in total

1.  Influence of the donors' clinical status on in vitro and in vivo tumor-cytotoxic activation of interleukin-2-exposed lymphocytes and their circulation in different organs.

Authors:  M Rodolfo; C Salvi; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Indium-111 chloride imaging in patients with suspected abscesses: concise communication.

Authors:  B A Sayle; S Balachandran; C A Rogers
Journal:  J Nucl Med       Date:  1983-12       Impact factor: 10.057

3.  Intracellular fluorescent labelling of cells for analysis of lymphocyte migration.

Authors:  M Brenan; C R Parish
Journal:  J Immunol Methods       Date:  1984-11-16       Impact factor: 2.303

4.  Fate of H2-activated T lymphocytes in syngeneic hosts. I. Fate in lymphoid tissues and intestines traced with 3H-thymidine, 125I-deoxyuridine and 51chromium.

Authors:  J Sprent
Journal:  Cell Immunol       Date:  1976-02       Impact factor: 4.868

5.  Influence of T cells on the expression of lymphokine-activated killer cell activity and in vivo tissue distribution.

Authors:  A A Maghazachi; R H Goldfarb; R B Herberman
Journal:  J Immunol       Date:  1988-12-01       Impact factor: 5.422

6.  In vivo distribution and tissue localization of highly purified rat lymphokine-activated killer (LAK) cells.

Authors:  A A Maghazachi; R B Herberman; N L Vujanovic; J C Hiserodt
Journal:  Cell Immunol       Date:  1988-08       Impact factor: 4.868

7.  Selective toxicity of rhodamine 123 in carcinoma cells in vitro.

Authors:  T J Lampidis; S D Bernal; I C Summerhayes; L B Chen
Journal:  Cancer Res       Date:  1983-02       Impact factor: 12.701

8.  In vivo and in vitro effect of adoptive immunotherapy of experimental murine brain tumors using lymphokine-activated killer cells.

Authors:  N Takai; R Tanaka; S Yoshida; N Hara; T Saito
Journal:  Cancer Res       Date:  1988-04-15       Impact factor: 12.701

9.  Lymphokine-activated killer cells in rats. III. A simple method for the purification of large granular lymphocytes and their rapid expansion and conversion into lymphokine-activated killer cells.

Authors:  N L Vujanovic; R B Herberman; A A Maghazachi; J C Hiserodt
Journal:  J Exp Med       Date:  1988-01-01       Impact factor: 14.307

10.  Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

Authors:  S A Rosenberg; J J Mulé; P J Spiess; C M Reichert; S L Schwarz
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

View more
  5 in total

1.  Confusion about the tissue distribution of lymphokine-activated killer (LAK) cells.

Authors:  A A Maghazachi
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

2.  Tissue distribution of adoptively transferred adherent lymphokine-activated killer cells assessed by different cell labels.

Authors:  P Basse; R B Herberman; M Hokland; R H Goldfarb
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

3.  Antitumour efficacy of lymphokine-activated killer cells loaded with ricin against experimentally induced lung metastases.

Authors:  P Zanovello; A Rosato; V Bronte; S Mandruzzato; V Cerundolo; D Collavo
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

4.  Curative effects of combination therapy with lentinan and interleukin-2 against established murine tumors, and the role of CD8-positive T cells.

Authors:  M Suzuki; T Kikuchi; F Takatsuki; J Hamuro
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

5.  Delivery of methoxymorpholinyl doxorubicin by interleukin 2-activated NK cells: effect in mice bearing hepatic metastases.

Authors:  L Quintieri; A Rosato; N Amboldi; C Vizler; D Ballinari; P Zanovello; D Collavo
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.